IN2012DN06436A - - Google Patents

Info

Publication number
IN2012DN06436A
IN2012DN06436A IN6436DEN2012A IN2012DN06436A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A IN 6436DEN2012 A IN6436DEN2012 A IN 6436DEN2012A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A
Authority
IN
India
Prior art keywords
acceptable salt
pharmaceutically acceptable
piperazine
pharmaceutically
dioxoethyl
Prior art date
Application number
Other languages
English (en)
Inventor
Lin Pin-Fang
Nowicka-Sans Beata
Yamanaka Gregory
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IN2012DN06436A publication Critical patent/IN2012DN06436A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN6436DEN2012 2004-03-24 2005-03-01 IN2012DN06436A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (fr) 2004-03-24 2005-03-01 Methodes de traitement d'une infection a vih

Publications (1)

Publication Number Publication Date
IN2012DN06436A true IN2012DN06436A (fr) 2015-10-09

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6436DEN2012 IN2012DN06436A (fr) 2004-03-24 2005-03-01

Country Status (30)

Country Link
US (1) US7776863B2 (fr)
EP (1) EP1732604B1 (fr)
JP (1) JP4847441B2 (fr)
KR (1) KR101158140B1 (fr)
CN (1) CN1956720B (fr)
AR (1) AR048333A1 (fr)
AT (1) ATE474602T1 (fr)
AU (1) AU2005235116B2 (fr)
BR (1) BRPI0509140A (fr)
CA (1) CA2561146C (fr)
CY (1) CY1111613T1 (fr)
DE (1) DE602005022420D1 (fr)
DK (1) DK1732604T3 (fr)
ES (1) ES2347801T3 (fr)
GE (1) GEP20104925B (fr)
HR (1) HRP20100434T1 (fr)
IL (1) IL178141A (fr)
IN (1) IN2012DN06436A (fr)
MY (1) MY144318A (fr)
NO (1) NO337116B1 (fr)
NZ (1) NZ549778A (fr)
PE (1) PE20060148A1 (fr)
PL (1) PL1732604T3 (fr)
PT (1) PT1732604E (fr)
RU (1) RU2367439C2 (fr)
SI (1) SI1732604T1 (fr)
TW (1) TWI347184B (fr)
UA (1) UA88463C2 (fr)
WO (1) WO2005102392A2 (fr)
ZA (1) ZA200607959B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007058322A1 (fr) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Composé contenant un groupe basique et son utilisation
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
JP5433691B2 (ja) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Hiv結合阻害剤としてのジケトピペリジン誘導体
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US20110290821A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
EP2601174B1 (fr) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Dérivés d'oxoacétyl pipérazinamide à substitution indole et azaindole
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
SG191841A1 (en) 2011-01-31 2013-08-30 Bristol Myers Squibb Co Methods of making hiv attachment inhibitor prodrug compound and intermediates
EP2696937B1 (fr) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Dérivés de thioamide, d'amidoxine et d'amidrazone comme inhibiteurs de l'attachement du vih
ES2609579T3 (es) 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (fr) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Dérivés d'hydrazine cycliques en tant qu'inhibiteurs de fixation du vih
WO2014025852A1 (fr) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Dérivés d'alcène tricycliques en tant qu'inhibiteurs d'attachement du vih
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
US9586957B2 (en) * 2013-03-27 2017-03-07 VIIV Healthcare UK (No.5) Limited 2-keto amide derivatives as HIV attachment inhibitors
CN107847514A (zh) * 2015-06-23 2018-03-27 西托戴恩股份有限公司 炎症、癌症、自身免疫和其它病症中ccl5配体结合ccr5受体的抑制作用和ccr5/ccl5轴信号传导的改变
WO2023172635A1 (fr) * 2022-03-08 2023-09-14 Emory University Modèle prédictif pour variants associés à la résistance aux médicaments et ses applications théranostiques
US12425371B2 (en) * 2022-09-16 2025-09-23 Cisco Technology, Inc. System and method for providing SCHC-based edge firewalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281960T3 (es) * 1998-03-02 2007-10-01 The University Of North Carolina At Chapel Hill Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso.
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2192870C1 (ru) * 2001-07-02 2002-11-20 Закрытое акционерное общество "Агрофарм ПитерСиб" Антивирусная композиция, способ получения ее активной компоненты и способ лечения вич-инфицированных больных этой композицией
BR0214842A (pt) * 2001-12-12 2005-01-11 Bristol Myers Squibb Co Inibidores de integrase hiv
BRPI0215050B8 (pt) * 2001-12-21 2021-05-25 Anormed Inc compostos heterocíclicos de ligação a receptor de quimiocina, seus usos no tratamento de condições relacionadas aos receptores de quimiocinas, doenças inflamatórias, alérgicas e autoimunes, bem como composições farmacêuticas que os compreendem

Also Published As

Publication number Publication date
JP4847441B2 (ja) 2011-12-28
ZA200607959B (en) 2008-06-25
KR101158140B1 (ko) 2012-06-19
WO2005102392A2 (fr) 2005-11-03
RU2006137555A (ru) 2008-04-27
CY1111613T1 (el) 2015-10-07
PE20060148A1 (es) 2006-03-04
CN1956720A (zh) 2007-05-02
NO20064547L (no) 2006-10-06
GEP20104925B (en) 2010-03-25
ES2347801T3 (es) 2010-11-04
DE602005022420D1 (de) 2010-09-02
WO2005102392A3 (fr) 2006-07-20
RU2367439C2 (ru) 2009-09-20
NZ549778A (en) 2010-09-30
TW200538117A (en) 2005-12-01
IL178141A (en) 2010-11-30
US20050215545A1 (en) 2005-09-29
AR048333A1 (es) 2006-04-19
CA2561146A1 (fr) 2005-11-03
DK1732604T3 (da) 2010-11-15
AU2005235116A1 (en) 2005-11-03
JP2007530540A (ja) 2007-11-01
MY144318A (en) 2011-08-29
HRP20100434T1 (hr) 2010-09-30
SI1732604T1 (sl) 2010-10-29
PT1732604E (pt) 2010-09-24
US7776863B2 (en) 2010-08-17
KR20070011322A (ko) 2007-01-24
PL1732604T3 (pl) 2010-12-31
ATE474602T1 (de) 2010-08-15
AU2005235116B2 (en) 2011-03-31
CN1956720B (zh) 2010-12-15
NO337116B1 (no) 2016-01-25
BRPI0509140A (pt) 2007-09-04
EP1732604B1 (fr) 2010-07-21
IL178141A0 (en) 2006-12-31
EP1732604A2 (fr) 2006-12-20
UA88463C2 (ru) 2009-10-26
TWI347184B (en) 2011-08-21
HK1096540A1 (en) 2007-06-01
CA2561146C (fr) 2013-12-24

Similar Documents

Publication Publication Date Title
IN2012DN06436A (fr)
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
NZ627824A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
TW200621762A (en) Novel compounds
GB0112348D0 (en) Compounds
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
MY132106A (en) New pyridazin-3(2h)-one derivatives
SE0202463D0 (sv) Novel compounds
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
EP2272516A3 (fr) Composé d'oxoquinoline 4 et utilisation associée en tant qu'inhibiteur contre l'intégrase du HIV
WO2008142055A3 (fr) Agents antiviraux
WO2006086447A3 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
GB0114286D0 (en) Nucleoside Derivatives
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
CA2322900A1 (fr) Derives de substitution 2-(hetero)aryl purin-6-ones en tant qu'inhibiteurs de la phosphodiesterase
EA200601654A1 (ru) Ингибиторы интегразы вич
WO2004030611A3 (fr) Inhibiteurs non nucleosidiques de transcriptases inverses
GB0106661D0 (en) Pharmaceutically active compounds
MY144773A (en) 6-(heterocycle-susbtituted benzyl) -4-oxoquinoline compound and use of the same as hiv integrase inhibitor
CA2668320A1 (fr) Utilisation de 3-alpha-androstanediol, eventuellement en combinaison avec un agoniste 5-ht1a, dans le traitement du dysfonctionnement sexuel
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS